Archangels, the Edinburgh-based angel syndicate that describes itself as the longest continuously operating angel investment group in the world, has leveraged £17.9 million of investment into Scottish scale-ups in the first six months of 2026, backing early-stage technology and life science companies through a run of significant funding rounds.archangelsonline
The figure comprises £7.2 million invested directly by Archangels’ members alongside £10.7 million of co-investment secured from partner investors. The H1 pace tracks closely with the run-rate that took Archangels to a record annual total of £41.1 million in 2025 — a 50 per cent uplift on 2024’s £27.3 million, and the strongest single year in the syndicate’s history, per the group’s year-end report.angelcapital
The named H1 deals
Two headline transactions dominate the first-half activity.
University of Edinburgh spin-out Bioliberty secured a £6.2 million Series A round led by the Scottish National Investment Bank, with participation from Archangels and co-investors including Eos Advisory, Old College Capital, Hanna Capital SEZC and new investor Conduit Connect. The round forms part of £7.7 million ($10.5 million) raised by Bioliberty over the past ten months and, according to Archangels, will fund product development and manufacturing in Scotland alongside further commercial expansion in the United States. Bioliberty’s AI-powered soft-robotic wearable platform for post-acute rehabilitation is already in use across a number of leading American rehabilitation facilities.
The second named deal is Biocaptiva, another University of Edinburgh spin-out, which closed a £1.6 million seed round led by Archangels. Biocaptiva is commercialising its patented msX magnetic bead platform for preparing blood samples for liquid biopsy — a technology designed to capture cell-free DNA directly from whole blood, simplifying sample preparation and enabling automation of a step that has to date been a bottleneck in the emerging liquid-biopsy diagnostics market.
Beyond the two named rounds, Archangels also confirmed continued portfolio activity through the first half, with Scottish biotech Bead BioPharma emerging from stealth mode on 8 June 2026 with a novel cancer drug platform, and prior participation earlier in 2026 in the £6 million round for climate-data business Earth Blox alongside PXN Ventures. Archangels’ own H1 disclosure specifically named Bioliberty and Biocaptiva as the flagship transactions of the six-month period.archangelsonline
What the numbers say about the Scottish angel market
The H1 total confirms that the record set in 2025 was not a one-year spike. At £17.9 million by mid-year, Archangels is on a trajectory that — assuming a broadly similar second-half deployment — could deliver a second consecutive year above £35 million.
The mix inside the number is also notable. Direct member investment of £7.2 million in H1 is close to the £6.4 million half-year run-rate implied by 2025’s £12.8 million full-year member deployment, suggesting Archangels’ own members are writing cheques at a steady pace rather than pulling back. The £10.7 million co-investment component confirms the trend of syndicates crowding-in outside capital, a pattern Angel Capital Scotland flagged in its 2025 wrap as the defining feature of Scotland’s early-stage market: fewer deals in aggregate, higher average deal size, and a growing role for angel syndicates in assembling institutional co-investment around Scottish scale-ups.angelcapital
For context, Angel Capital Scotland’s most recent market data showed the total value of private capital committed via Scottish angel networks rose from £100.6 million to £106.4 million year on year, even as deal count fell slightly from 94 to 91 — the same story visible in Archangels’ own numbers, at a syndicate level.
In Case You Missed It:
The Edinburgh life-sciences signal
Two of Archangels’ three named 2026 transactions — Bioliberty and Biocaptiva — are University of Edinburgh spin-outs. Bead BioPharma, which emerged from stealth in June, sits in the same broad Edinburgh life-sciences cluster. That concentration is not accidental: Archangels has been an active backer of Edinburgh-originated biotech and medtech for more than a decade, and the H1 2026 deployment reinforces the syndicate’s growing weight in the city’s translational life-sciences pipeline.
For the wider Scottish scale-up ecosystem, the read-through is straightforward. Angel syndicate capital continues to flow into Scottish tech and life-science companies at record levels, with co-investment increasingly institutionalised and Scottish National Investment Bank participation showing up as a lead-investor role in flagship rounds. That is a healthier picture than the tone of the wider UK early-stage market this year would suggest — and one that positions Scotland’s angel infrastructure as one of the more resilient components of the country’s growth-financing stack.
